Your browser doesn't support javascript.
loading
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Jindal, Tanya; Zhu, Xiaolin; Bose, Rohit; Kumar, Vipul; Maldonado, Edward; Deshmukh, Prianka; Shipp, Chase; Feng, Stephanie; Johnson, Michelle S; Angelidakis, Austin; Kwon, Daniel; Borno, Hala T; de Kouchkovsky, Ivan; Desai, Arpita; Aggarwal, Rahul; Fong, Lawrence; Small, Eric J; Wong, Anthony; Porten, Sima; Chou, Jonathan; Friedlander, Terence; Koshkin, Vadim S.
Afiliação
  • Jindal T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Zhu X; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Bose R; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Kumar V; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Maldonado E; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Deshmukh P; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Shipp C; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Feng S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Johnson MS; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Angelidakis A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Kwon D; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Borno HT; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • de Kouchkovsky I; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Desai A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Aggarwal R; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Fong L; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Small EJ; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Wong A; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Porten S; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Chou J; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Friedlander T; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
  • Koshkin VS; Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Front Oncol ; 13: 1161089, 2023.
Article em En | MEDLINE | ID: mdl-37091148

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article